Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of evolocumab in patients with clinically evident cardiovascular disease
2015-004780-36Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evolocumab in hypercholesterolemia, dyslipidemia and cardiac morbidity, sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Mar 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiadyslipidemiacardiac morbidity
Beyond the preview
Go deeper on 2015-004780-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004780-36.